SEARCH

SEARCH BY CITATION

REFERENCES

  • 1
    National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Chronic Myelogenous Leukemia. Version 1. 2010. Fort Washington, Pa: National Comprehensive Cancer Network; 2009.
  • 2
    Rowley JD. Letter: a new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973; 243: 290-293.
  • 3
    Melo JV, Deininger MW. Biology of chronic myelogenous leukemia—signaling pathways of initiation and transformation. Hematol Oncol Clin North Am. 2004; 18: 545-568.
  • 4
    Ren R. Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005; 5: 172-183.
  • 5
    Faderl S, Talpaz M, Estrov Z, Kantarjian HM. Chronic myelogenous leukemia: biology and therapy. Ann Intern Med. 1999; 131: 207-219.
  • 6
    Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999; 341: 164-172.
  • 7
    Goldman JM, Melo JV. Chronic myeloid leukemia—advances in biology and new approaches to treatment. N Engl J Med. 2003; 349: 1451-1464.
  • 8
    Advani AS, Pendergast AM. Bcr-Abl variants: biological and clinical aspects. Leuk Res. 2002; 26: 713-720.
  • 9
    Buchdunger E, Zimmermann J, Mett H, et al. Inhibition of the Abl protein-tyrosine kinase in vitro and in vivo by a 2-phenylaminopyrimidine derivative. Cancer Res. 1996; 56: 100-104.
  • 10
    Buchdunger E, Cioffi CL, Law N, et al. Abl protein-tyrosine kinase inhibitor STI571 inhibits in vitro signal transduction mediated by c-kit and platelet-derived growth factor receptors. J Pharmacol Exp Ther. 2000; 295: 139-145.
  • 11
    Okuda K, Weisberg E, Gilliland DG, Griffin JD. ARG tyrosine kinase activity is inhibited by STI571. Blood. 2001; 97: 2440-2448.
  • 12
    Dewar AL, Zannettino AC, Hughes TP, Lyons AB. Inhibition of c-fms by imatinib: expanding the spectrum of treatment. Cell Cycle. 2005; 4: 851-853.
  • 13
    Heinrich MC, Griffith DJ, Druker BJ, Wait CL, Ott KA, Zigler AJ. Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood. 2000; 96: 925-932.
  • 14
    Kantarjian HM, Giles F, Quintas-Cardama A, Cortes J. Important therapeutic targets in chronic myelogenous leukemia. Clin Cancer Res. 2007; 13: 1089-1097.
  • 15
    Weisberg E, Manley PW, Breitenstein W, et al. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005; 7: 129-141.
  • 16
    Hantschel O, Rix U, Superti-Furga G. Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib. Leuk Lymphoma. 2008; 49: 615-619.
  • 17
    Druker BJ, Sawyers CL, Kantarjian H, et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome. N Engl J Med. 2001; 344: 1038-1042.
  • 18
    Druker BJ, Talpaz M, Resta DJ, et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med. 2001; 344: 1031-1037.
  • 19
    Druker BJ, Tamura S, Buchdunger E, et al. Effects of a selective inhibitor of the Abl tyrosine kinase on the growth of Bcr-Abl positive cells. Nat Med. 1996; 2: 561-566.
  • 20
    Hochhaus A, Druker B, Sawyers C, et al. Favorable long-term follow-up results over 6 years for response, survival, and safety with imatinib mesylate therapy in chronic-phase chronic myeloid leukemia after failure of interferon-alpha treatment [abstract]. Blood (ASH Annual Meeting Abstracts). 2008; 111: 1039-1043. Abstract 186.
  • 21
    Hughes TP, Kaeda J, Branford S, et al. Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia. N Engl J Med. 2003; 349: 1423-1432.
  • 22
    O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2003; 348: 994-1004.
  • 23
    Hochhaus A, O'Brien SG, Guilhot F, et al. Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia. Leukemia. 2009; 23: 1054-1061.
  • 24
    O'Brien SG, Guilhot F, Goldman JM, et al. International randomized study of interferon versus STI571 (IRIS) 7-year follow-up: sustained survival, low rate of transformation and increased rate of major molecular response (MMR) in patients (pts) with newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP) treated with imatinib (IM) [abstract]. Blood. 2008; 112: 76 Abstract 186.
  • 25
    Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med. 2006; 355: 2408-2417.
  • 26
    Deininger M, Schleuning M, Greinix H, et al. The effect of prior exposure to imatinib on transplant-related mortality. Haematologica. 2006; 91: 452-459.
  • 27
    Hess G, Bunjes D, Siegert W, et al. Sustained complete molecular remissions after treatment with imatinib-mesylate in patients with failure after allogeneic stem cell transplantation for chronic myelogenous leukemia: results of a prospective phase II open-label multicenter study. J Clin Oncol. 2005; 23: 7583-7593.
  • 28
    Kantarjian HM, Talpaz M, O'Brien S, et al. Survival benefit with imatinib mesylate versus interferon-alpha-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood. 2006; 108: 1835-1840.
  • 29
    Roy L, Guilhot J, Krahnke T, et al. Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between 2 phase 3 trials. Blood. 2006; 108: 1478-1484.
  • 30
    Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009; 27: 6041-6051.
  • 31
    Hughes T, Deininger M, Hochhaus A, et al. Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results. Blood. 2006; 108: 28-37.
  • 32
    Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008; 111: 1774-1780.
  • 33
    Press RD, Galderisi C, Yang R, et al. A half-log increase in BCR-ABL RNA predicts a higher risk of relapse in patients with chronic myeloid leukemia with an imatinib-induced complete cytogenetic response. Clin Cancer Res. 2007; 13: 6136-6143.
  • 34
    Larson RA, Druker BJ, Guilhot F, et al. Imatinib pharmacokinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS study. Blood. 2008; 111: 4022-4028.
  • 35
    Gorre ME, Mohammed M, Ellwood K, et al. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science. 2001; 293: 876-880.
  • 36
    Corbin AS, La Rosee P, Stoffregen EP, Druker BJ, Deininger MW. Several Bcr-Abl kinase domain mutants associated with imatinib mesylate resistance remain sensitive to imatinib. Blood. 2003; 101: 4611-4614.
  • 37
    Khorashad JS, Anand M, Marin D, et al. The presence of a BCR-ABL mutant allele in CML does not always explain clinical resistance to imatinib. Leukemia. 2006; 20: 658-663.
  • 38
    Branford S, Rudzki Z, Walsh S, et al. Detection of BCR-ABL mutations in patients with CML treated with imatinib is virtually always accompanied by clinical resistance, and mutations in the ATP phosphate-binding loop (P-loop) are associated with a poor prognosis. Blood. 2003; 102: 276-283.
  • 39
    Soverini S, Martinelli G, Rosti G, et al. ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of progression to blast crisis and shorter survival: a study by the GIMEMA Working Party on Chronic Myeloid Leukemia. J Clin Oncol. 2005; 23: 4100-4109.
  • 40
    Shah NP, Nicoll JM, Nagar B, et al. Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2: 117-125.
  • 41
    Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004; 305: 399-401.
  • 42
    O'Hare T, Eide CA, Deininger MW. Bcr-Abl kinase domain mutations, drug resistance, and the road to a cure for chronic myeloid leukemia. Blood. 2007; 110: 2242-2249.
  • 43
    Kantarjian H, Talpaz M, O'Brien S, et al. High-dose imatinib mesylate therapy in newly diagnosed Philadelphia chromosome-positive chronic phase chronic myeloid leukemia. Blood. 2004; 103: 2873-2878.
  • 44
    Hochhaus A, Kreil S, Corbin AS, et al. Molecular and chromosomal mechanisms of resistance to imatinib (STI571) therapy. Leukemia. 2002; 16: 2190-2196.
  • 45
    Nicolini FE, Corm S, Le QH, et al. Mutation status and clinical outcome of 89 imatinib mesylate-resistant chronic myelogenous leukemia patients: a retrospective analysis from the French intergroup of CML (Fi(phi)-LMC GROUP). Leukemia. 2006; 20: 1061-1066.
  • 46
    Kantarjian HM, Talpaz M, O'Brien S, et al. Dose escalation of imatinib mesylate can overcome resistance to standard-dose therapy in patients with chronic myelogenous leukemia. Blood. 2003; 101: 473-475.
  • 47
    Jabbour E, Kantarjian HM, Jones D, et al. Imatinib mesylate dose escalation is associated with durable responses in patients with chronic myeloid leukemia after cytogenetic failure on standard-dose imatinib therapy. Blood. 2009; 113: 2154-2160.
  • 48
    Rea D, Etienne G, Corm S, et al. Imatinib dose escalation for chronic phase-chronic myelogenous leukaemia patients in primary suboptimal response to imatinib 400 mg daily standard therapy. Leukemia. 2009; 23: 1193-1196.
  • 49
    Kantarjian HM, Larson RA, Guilhot F, et al. Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase. Cancer. 2009; 115: 551-560.
  • 50
    Hughes T, Branford S, Reynolds J, et al. Higher dose imatinib (600 mg/day) with selective intensification in newly diagnosed CML patients in chronic phase: cytogenetic response rates at 12 months are superior to IRIS [abstract]. Blood. 2004; 104: 286a. Abstract 1001.
  • 51
    Cortes J, Baccarani M, Guilhot F, et al. A phase III, randomized, open-label study of 400 mg versus 800 mg of imatinib mesylate (IM) in patients (pts) with newly diagnosed, previously untreated chronic myeloid leukemia in chronic phase (CML-CP) using molecular endpoints: 1-year results of TOPS (Tyrosine Kinase Inhibitor Optimization and Selectivity) Study [abstract]. Blood. 2008; 112: 130-131. Abstract 335.
  • 52
    Baccarani M, Castagnetti F, Simonsson B, et al. Cytogenetic and molecular response to imatinib in high risk (Sokal) chronic myeloid leukemia (CML): results of a European LeukemiaNet prospective study comparing 400 mg and 800 mg front-line [abstract]. Blood. 2008; 112: 75. Abstract 185.
  • 53
    Andreas AP, Wolf DW, Fong DF, et al. High doses of imatinib mesylate (800 mg/day) significantly improve rates of major and complete cytogenetic remissions (MCR, CCR)—results from the first planned interim analysis of a multicenter, randomised, 2 arm phase III study comparing imatinib standard dose (400 mg/day) with imatinib high dose (800 mg/day) [abstract]. Haematologica. 2008; 93( 1 suppl): 162. Abstract 0406.
  • 54
    Cortes JE, Baccarani M, Guilhot F, et al. First report of the TOPS study: a randomized phase III trial of 400 mg vs 800 mg imatinib in patients with newly diagnosed, previously untreated CML in chronic phase using molecular endpoints [abstract]. Haematologica. 2008; 93( 1 suppl): 160. Abstract 0402.
  • 55
    Golemovic M, Verstovsek S, Giles F, et al. AMN107, a novel aminopyrimidine inhibitor of Bcr-Abl, has in vitro activity against imatinib-resistant chronic myeloid leukemia. Clin Cancer Res. 2005; 11: 4941-4947.
  • 56
    Ray A, Cowan-Jacob SW, Manley PW, Mestan J, Griffin JD. Identification of BCR-ABL point mutations conferring resistance to the Abl kinase inhibitor AMN107 (nilotinib) by a random mutagenesis study. Blood. 2007; 109: 5011-5015.
  • 57
    Kantarjian H, Giles F, Wunderle L, et al. Nilotinib in imatinib-resistant CML and Philadelphia chromosome-positive ALL. N Engl J Med. 2006; 354: 2542-2551.
  • 58
    Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007; 110: 3540-3546.
  • 59
    Kantarjian HM, Giles F, Bhalla KN, et al. Nilotinib in chronic myeloid leukemia patients in chronic phase (CMLCP) with imatinib resistance or intolerance: 2-year follow-up results of a phase 2 study [abstract]. Blood. 2008; 112: 1112. Abstract 3238.
  • 60
    Giles F, le Coutre P, Bhalla K, et al. Efficacy and tolerability of nilotinib in chronic myeloid leukemia patients in chronic phase (CML-CP) who failed prior imatinib and dasatinib therapy: updated results of a phase 2 study [abstract]. Blood. 2008; 112: 1110. Abstract 3234.
  • 61
    Abruzzese E, Gozzetti A, Galimberti S, et al. Characterization of Ph-negative abnormal clones emerging during imatinib therapy. Cancer. 2007; 109: 2466-2472.
  • 62
    Novartis Pharmaceuticals Corporation. Tasigna (nilotinib) [Package Insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
  • 63
    Jabbour E, Kantarjian HM, Baccarani M, et al. Minimal cross-intolerance between nilotinib and imatinib in patients with imatinib-intolerant chronic myeloid leukemia in chronic phase (CML-CP) or accelerated phase (CML-AP) [abstract]. Blood. 2008; 112: 1103. Abstract 3215.
  • 64
    Hughes T, Saglio G, Branford S, et al. Impact of baseline BCR-ABL mutations on response to nilotinib in patients with chronic myeloid leukemia in chronic. J Clin Oncol. 2009; 27: 4204-4210.
  • 65
    Vajpai N, Strauss A, Fendrich G, et al. Solution conformations and dynamics of ABL kinase-inhibitor complexes determined by NMR substantiate the different binding modes of imatinib/nilotinib and dasatinib. J Biol Chem. 2008; 283: 18292-18302.
  • 66
    Wisniewski D, Lambek CL, Liu C, et al. Characterization of potent inhibitors of the Bcr-Abl and the c-kit receptor tyrosine kinases. Cancer Res. 2002; 62: 4244-4255.
  • 67
    Soverini S, Colarossi S, Gnani A, et al. Resistance to dasatinib in Philadelphia-positive leukemia patients and the presence or the selection of mutations at residues 315 and 317 in the BCR-ABL kinase domain. Haematologica. 2007; 92: 401-404.
  • 68
    Melnick JS, Janes J, Kim S, et al. An efficient rapid system for profiling the cellular activities of molecular libraries. Proc Natl Acad Sci U S A. 2006; 103: 3153-3158.
  • 69
    Das J, Chen P, Norris D, et al. 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J Med Chem. 2006; 49: 6819-6832.
  • 70
    Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008; 22: 1200-1206.
  • 71
    Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or -intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007; 109: 4143-4150.
  • 72
    Cortes J, Kim DW, Raffoux E, et al. Efficacy and safety of dasatinib in imatinib-resistant or -intolerant patients with chronic myeloid leukemia in blast phase. Leukemia. 2008; 22: 2176-2183.
  • 73
    Kantarjian H, Pasquini R, Hamerschlak N, et al. Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia after failure of first-line imatinib: a randomized phase 2 trial. Blood. 2007; 109: 5143-5150.
  • 74
    Shah NP, Kantarjian HM, Kim DW, et al. Intermittent target inhibition with dasatinib 100 mg once daily preserves efficacy and improves tolerability in imatinib-resistant and -intolerant chronic-phase chronic myeloid leukemia. J Clin Oncol. 2008; 26: 3204-3212.
  • 75
    Kantarjian HM, Kim DW, Dorlhiac-Llacer P, et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with accelerated phase chronic myeloid leukemia (CML-AP):2-year follow-up data from CA180-035 [abstract]. Blood. 2008; 112: 1106-1107. Abstract 3224.
  • 76
    Saglio G, Kantarjian HM, Hochhaus A, et al. Dasatinib 140 mg once daily (QD) demonstrates equivalent efficacy and improved safety compared with 70 mg twice daily (BID) in patients with chronic myeloid leukemia in blast phase (CML-BP):2-year data from CA180-035 [abstract]. Blood. 2008; 112: 1107-1108. Abstract 3226.
  • 77
    Mueller MC, Cortes J, Kim DW, et al. Dasatinib efficacy in patients with chronic myeloid leukemia in chronic phase (CML-CP) and preexisting BCR-ABL mutations [abstract]. Blood. 2008; 112: 171-172. Abstract 449.
  • 78
    Cortes J, O'Brien S, Jones D, et al. Efficacy of nilotinib (formerly AMN107) in patients (pts) with newly diagnosed, previously untreated Philadelphia chromosome (Ph)-positive chronic myelogenous leukemia in early chronic phase (CML-CP) [abstract]. Blood. 2008; 112: 170. Abstract 446.
  • 79
    Rosti G, Castagnetti F, Poerio A, et al. High and early rates of cytogenetic and molecular response with nilotinib 800 mg daily as first line treatment of Ph-positive chronic myeloid leukemia in chronic phase: results of a phase 2 trial of the GIMEMA CML Working Party [abstract]. Blood. 2008; 112: 73-74. Abstract 181.
  • 80
    Cortes J, O'Brien S, Borthakur G, et al. Efficacy of dasatinib in patients (pts) with previously untreated chronic myelogenous leukemia (CML) in early chronic phase (CML-CP) [abstract]. Blood. 2008; 112: 74. Abstract 182.
  • 81
    Coluccia AM, Benati D, Dekhil H, De Filippo A, Lan C, Gambacorti-Passerini C. SKI-606 decreases growth and motility of colorectal cancer cells by preventing pp60(c-Src)-dependent tyrosine phosphorylation of beta-catenin and its nuclear signaling. Cancer Res. 2006; 66: 2279-2286.
  • 82
    Golas JM, Arndt K, Etienne C, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003; 63: 375-381.
  • 83
    Golas JM, Lucas J, Etienne C, et al. SKI-606, a Src/Abl inhibitor with in vivo activity in colon tumor xenograft models. Cancer Res. 2005; 65: 5358-5364.
  • 84
    Cortes J, Kantarjian H, Baccarani M, et al. A phase 1/2 study of SKI-606, a dual inhibitor of Src and Abl kinases, in adult patients with Philadelphia chromosome positive (Ph+) chronic myelogenous leukemia (CML) or acute lymphoblastic leukemia relapsed, refractory or intolerant of imatinib [abstract]. Blood. 2006; 108: 54a. Abstract 168.
  • 85
    Puttini M, Coluccia AM, Boschelli F, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006; 66: 11314-13422.
  • 86
    Cortes J, Kantarjian HM, Kim D-W, et al. Efficacy and safety of bosutinib (SKI-606) in patients with chronic phase (CP) Ph+ chronic myeloid leukemia (CML) with resistance or intolerance to imatinib [abstract]. Blood. 2008; 112: 401. Abstract 1098.
  • 87
    Gambacorti-Passerini C, Pogliani EM, Baccarani M, et al. Bosutinib (SKI-606) demonstrates clinical activity and is well tolerated in patients with AP and BP CML and Ph+ ALL [abstract]. Blood. 2008; 112: 402. Abstract 1101.
  • 88
    Cortes J, Quintas-Cardama A, Garcia-Manero G, et al. Phase 1 study of tipifarnib in combination with imatinib for patients with chronic myelogenous leukemia in chronic phase after imatinib failure. Cancer. 2007; 110: 2000-2006.
  • 89
    Cortes J, Jabbour E, Daley GQ, et al. Phase 1 study of lonafarnib (SCH 66336) and imatinib mesylate in patients with chronic myeloid leukemia who have failed prior single-agent therapy with imatinib. Cancer. 2007; 110: 1295-1302.
  • 90
    Singh N, Kumar L, Kochupillae V, et al. To assess the response and toxicity of imatinib mesylate and low-dose cytarabine in imatinib non-responder chronic myeloid leukemia, chronic phase (CML-CP) patients: a pilot study [abstract]. J Clin Oncol. 2007; 25( 18 suppl): 680s. Abstract 17507.
  • 91
    Hurtado-Monroy R, Vargas P, Martinez A, et al. Imatinib (I) compared to I &plus cytarabine (Ara-C) for the frontline treatment of chronic phase (CP) chronic myeloid leukemia (CML) [abstract]. J Clin Oncol. 2007; 25( 18 suppl): 368s. Abstract 7048.
  • 92
    Hochhaus A, Neubauer A, Mueller MC, et al. Safety and efficacy of a combination of imatinib and pegylated interferon α2a (Pegasys) in newly diagnosed patients with chronic myelogenous leukemia—a phase II cohort study [abstract]. Blood. 2007; 110: 311a. Abstract 1027.
  • 93
    Hochhaus A, Neubauer A, Mueller MC, et al. Sustained molecular responses with interferon α2a maintenance therapy after imatinib plus IFN induction treatment for chronic phase chronic myelogenous leukemia [abstract]. Blood. 2007; 110: 16a-17a. Abstract 28.
  • 94
    Mahon F, Rea D, Guilhot F, et al. Persistence of complete molecular remission in chronic myeloid leukemia after imatinib discontinuation: interim analysis of the STIM trial [abstract]. J Clin Oncol. 2009; 27 (15 suppl): 376s. Abstract 7084.